Company Highlights Translational Oncology Platform at Leading Research Institution Event
Los Angeles, CA – 2023 — Avesta Bio was selected to present at The Lundquist Institute’s 2023 Innovation Annual Showcase, an event highlighting emerging scientific advancements and translational research initiatives advancing toward commercialization.
The Innovation Annual Showcase convenes researchers, clinicians, institutional leaders, and industry stakeholders to spotlight promising technologies and therapeutic platforms originating from academic and research environments. Companies selected to present are recognized for scientific rigor, translational potential, and alignment with advancing patient-centered innovation.
During the showcase, Avesta Bio outlined its platform strategy focused on targeting maladaptive cellular stress-response and drug-resistance pathways implicated in cancer progression. The presentation emphasized the company’s structured approach to intellectual property development, regulatory planning, and advancement toward early-stage clinical evaluation.
“Events like the Lundquist Innovation Showcase are critical in bridging the gap between discovery science and disciplined therapeutic development,” said Ian Akash Morrison, CEO of Avesta Bio. “We were honored to share our progress and engage with leaders committed to translating foundational biology into meaningful patient impact.”
Participation in the showcase reflects Avesta Bio’s early momentum in building academic and institutional relationships supporting its long-term development strategy. The company continues to advance its oncology platform through strategic collaborations across research, manufacturing, and clinical domains.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
Founded to translate rigorous academic discoveries into structured clinical development programs, Avesta Bio continues to expand its scientific and strategic partnerships.
For more information, visit: www.avestabio.com